Case Reports in Neurological Medicine

Case Reports in Neurological Medicine / 2011 / Article

Case Report | Open Access

Volume 2011 |Article ID 975152 |

Amer Awad, Olaf Stüve, Marlyn Mayo, Rafeed Alkawadri, Bachir Estephan, " Anti-Glutamic Acid Decarboxylase Antibody-Associated Ataxia as an Extrahepatic Autoimmune Manifestation of Hepatitis C Infection: A Case Report", Case Reports in Neurological Medicine, vol. 2011, Article ID 975152, 4 pages, 2011.

Anti-Glutamic Acid Decarboxylase Antibody-Associated Ataxia as an Extrahepatic Autoimmune Manifestation of Hepatitis C Infection: A Case Report

Academic Editor: José Luis González-Gutiérrez
Received23 May 2011
Accepted15 Jun 2011
Published10 Jul 2011


Extrahepatic immunological manifestations of hepatitis C virus (HCV) are well described. In addition, antiglutamic acid decarboxylase (GAD) antibody-associated cerebellar ataxia is well-established entity. However, there have been no reports in the literature of anti-GAD antibody-associated ataxia as an extrahepatic manifestation of HCV infection. We report the case of a young woman with chronic hepatitis C virus and multiple extrahepatic autoimmune diseases including Sjögren syndrome and pernicious anemia who presented with subacute midline cerebellar syndrome and was found to have positive antiglutamic acid decarboxylase (GAD) antibody in the serum and cerebrospinal fluid. An extensive diagnostic workup to rule out neoplastic growths was negative, suggesting the diagnosis of nonparaneoplastic antiglutamic acid decarboxylase antibody-associated cerebellar ataxia as an additional extrahepatic manifestation of hepatitis C virus infection. The patient failed to respond to high-dose steroids and intravenous immunoglobulin. Treatment with the monoclonal antibody rituximab stabilized the disease. We postulate that anti-GAD associated ataxia could be an extrahepatic manifestation of HCV infection.

1. Introduction

Hepatitis C virus (HCV) is commonly associated with autoimmune diseases as extrahepatic manifestations (EHM) [1] The most important autoimmune diseases associated with HCV are mixed essential cryoglobulinemia (MEC) [2] and Sjögren syndrome (SS) [3]. Other autoimmune diseases have been described in patients with HCV, but the association has not been well documented. These autoimmune diseases include HCV-associated arthritis [4], systemic lupus erythematosus [5], polyarteritis nodosa [6], antiphospholipid antibody syndrome [7], inflammatory myopathies [8], sarcoidosis [9], autoimmune thyroid disease [10], autoimmune glomerulonephritis [11], skin vasculitis [12], and autoimmune thrombocytopenia [13].

The pathogenesis of these EHM is still not fully understood, although most studies suggest that the presence of MEC, particular lymphotropism of the virus, molecular mimicry, and non-MEC autoimmune phenomena constitute the major pathogenic factors [14].

To our knowledge, there have been no previous reports of antiglutamic acid decarboxylase (GAD) antibody-associated cerebellar ataxia as an extrahepatic manifestation of chronic HCV infection. We report here a young woman with chronic HCV infection, who presented with subacute midline (vermis) cerebellar syndrome and tested positive for anti-GAD antibodies in the serum and the cerebrospinal fluid (CSF). We postulate that the patient has a postinfectious or parainfectious autoimmune disease caused by antibodies directed against the neuronal antigen GAD 65.

2. Case Report

The patient is a 48-year-old African American woman with past medical history significant for HCV secondary to blood transfusion, SS, pernicious anemia, and obesity status postbariatric surgery. She presented to the neurology clinic with history of subacute onset gait ataxia, intermittent vertigo, diplopia, oscillopsia, dysarthria, and dysphagia. The patient was initially treated with high-dose intravenous methylprednisolone (IVMP) followed by high-dose oral prednisone with modest response as her ataxia continued to progress. Based on the assumption that her symptoms were secondary to central nervous system (CNS) involvement of SS, she was treated with rituximab with no significant clinical improvement though it stabilized the disease. The patient also did not respond to intravenous immunoglobulin (IVIG) treatment. No history of alcohol use or malnutrition. Her neurological examination revealed hypometric saccades, mild dysarthria, truncal ataxia, and gait ataxia without limb ataxia. A motor exam was unremarkable, and sensory exam was positive for decreased vibratory sensation distally. An extensive workup was initiated. Abnormal results include HCV viral load 193,000 copies per mL, HCV genotype I, liver biopsy (stage I HCV disease), antinuclear antibody (Ab) (ANA) positive, SS-A positive (1 : 230), antiparietal cell Ab positive, anti-intrinsic factor (IF) Ab positive, small M spike on serum protein electrophoresis (SPEP) with normal 24-hour urine protein electrophoresis (UPEP), cerebrospinal fluid (CSF) oligoclonal bands (OCBs) positive with normal cell count and protein, and increased uptake on the right submandibular gland on positron emission tomography (PET). Pertinent negative/normal results include vitamin B12 (on supplements), folic acid (on supplements), vitamin B1 (thiamine on supplements), vitamin B6, vitamin E, lactate, pyruvate, thyroid stimulating hormone (TSH), copper, ceruloplasmin, urine heavy metals, human immunodeficiency virus (HIV), rapid plasma regain (RPR), SS-B, rheumatoid factor (RF), antineutrophilic cytoplasmic Ab (ANCA), antiphospholipid Ab (a PL), angiotensin-converting enzyme (ACE), antiendomysial Ab, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), C3, C4, cryoglobulins, paraneoplastic panel, anti-amphiphysin antibody, brain and spine magnetic resonance imaging (MRI) with contrast, bone scan, bone marrow biopsy, mammogram, Pap smear, computerized tomography (CT) of the chest, abdomen, and pelvis. The most remarkable finding was a positive anti-GAD 65 Ab in the serum (titer 113.65 units per mL) and in the CSF (titer 29.4 nmole/L with a normal range of <0.02 nmole/L) with positive OCBs despite treatment with steroids, IVIG, and Rituximab. The patient had numerous fasting blood sugars (FBS) done to exclude late onset diabetes. All the FBS values were within normal limits (80–95 mg/dL).

Antiviral therapy with interferon alpha (IFNα) and ribavirin was discussed with the hepatologist, but the patient was considered a poor candidate due to the possibility of exacerbation of a secondary autoimmune disease. Since the patient’s cerebellar syndrome was stabilized by rituximab, we continued maintenance therapy with close monitoring of her neurological status.

3. Discussion

The patient presented with symptoms and signs consistent with cerebellar vermis syndrome including hypometric saccades, truncal, and gait ataxia without limb ataxia [15, 16]. Thiamine and copper deficiency as potential causes of ataxia, which are common after Bariatric surgery [17, 18], were excluded by normal serum levels. The patient was on vitamin B12 and folic acid supplements. Brain and spine MRI excluded structural causes of ataxia. The thorough workup excluded other potential causes of ataxia including vitamin E deficiency [19], heavy metal toxicity [20, 21], celiac disease-associated ataxia [22]. Finally, numerous fasting blood sugar samples excluded late onset insulin-dependent diabetes mellitus.

The most striking abnormality was the finding of positive anti-GAD 65 Abs in the serum and the CSF. The positivity in the CSF confirms its pathogenic role in the patient’s ataxia. Anti-GAD 65 Ab has been associated with a myriad of disorders including insulin-dependent diabetes mellitus (IDDM) [23], stiff person syndrome (SPS) [24], limbic encephalitis [25], opsoclonus-myoclonus syndrome [26], epilepsy [27], and ataxia [27, 28]. The positivity for anti-GAD dictated a thorough neoplastic workup because anti-GAD antibody is often associated with neoplastic growth in the context of a paraneoplastic neurological disorder. This is especially true if anti-amphiphysin antibodies are also present [29]. A comprehensive neoplastic workup was negative, and a paraneoplastic antibody panel was negative as well. The clinical picture in parallel with the lab findings suggests the diagnosis of nonparaneoplastic anti-GAD Ab-associated ataxia. Nevertheless, the continuous and long-term search for occult neoplasms is required to confirm the nonparaneoplastic origin since neurological paraneoplastic disorders can precede the diagnosis of occult malignancies by a long period of time.

While ataxia associated with anti-GAD antibodies is a well-described entity, this patient is unusual as her underlying chronic medical condition is a viral infection of the liver, namely, HCV. A thorough literature review did not uncover previous reports of such an association. We propose that the anti-GAD ataxia in this patient is an extrahepatic autoimmune manifestation of HCV. The association might be incidental, but there are 2 factors that make the association more than just incidental. The first one is the extreme rarity of anti-GAD ataxia making the mathematical possibility of both occurring in the same patient very highly unlikely. The second factor, and the more important reason is the finding of remarkable molecular mimicry between HCV and GAD 65 [30].

With regard to the etiology of this clinical presentation, we hypothesize that this patient is suffering from a para-infectious autoimmune disease caused by of molecular mimicry. Not unlike in a paraneoplastic syndrome, it is conceivable that a neuronal antigen-like determinant is ectopically expressed. Only in this case, it would be expressed not by a malignant cell, but instead either by HCV, or by a host cell infected with HCV. Consequently, this antigen is recognized as “foreign”. Initially, the viral neuronal-antigen-like determinant is recognized at the site of inoculation by cells of the innate immune system, which then present linear epitopes to T cells. These T cells, once activated, in turn cross-activates antigen-specific B cells. Such activated autoreactive T cells and B cells readily entering the CNS during the course of routine immune surveillance [31]. Incidentally, these cells may encounter a neuronal antigen in the cerebellum that closely resembles the viral neuronal-antigen-like determinant they were originally primed against. Following reactivation by CNS intrinsic antigen presenting cells, these T cells and B cells now initiate and autoimmune disease, which includes the recruitment of nonantigen specific immune cells from the blood that amplify the inflammation.

It would be extremely difficult to test our hypothesis in a human patient. In animal models, the cascade of events described above was successfully demonstrated experimentally by transgenic insertion of a lymphocytic choriomeningitis virus (LCMV) antigen in murine oligodendrocytes. Following intraperitoneal inoculation of these animals with LCMV, the infection was cleared at the entry site. However, 7–14 days later, the inflammation of the CNS was detected, and the experimental animals displayed functional clinical deficits [32].

Treatment of anti-GAD syndrome is not well established yet. However, favorable responses to steroids, IVIG, and plasma exchange were reported in the literature [3335]. Rituximab was shown to be safe and helpful in treatment of EHM of HCV [36, 37]. More importantly, antiviral treatment of HCV can improve EHM [38] but may worsen the course of autoimmune disorders associated with HCV [39].

4. Conclusion

Our case of HCV-associated anti-GAD ataxia should help alert neurologists and other physicians treating patients with HCV to the presence of this entity. Patients with HCV and neurological symptoms should be evaluated for neuroimmunological disorders by running a comprehensive immune workup including testing for anti-GAD Ab. Early diagnosis is crucial to stabilize the disease and prevent its progression since reversing neuropathology is currently not feasible. Further studies are crucial to study this association and the exact immunopathogenesis behind it.


  1. S. Ferri, L. Muratori, M. Lenzi, A. Granito, F. B. Bianchi, and D. Vergani, “HCV and autoimmunity,” Current Pharmaceutical Design, vol. 14, no. 17, pp. 1678–1685, 2008. View at: Publisher Site | Google Scholar
  2. C. Ferri, “Mixed cryoglobulinemia,” Orphanet Journal of Rare Diseases, vol. 3, no. 1, article 25, 2008. View at: Publisher Site | Google Scholar
  3. M. Ramos-Casals, S. Muñoz, F. Medina et al., “Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry),” Journal of Rheumatology, vol. 36, no. 7, pp. 1442–1448, 2009. View at: Publisher Site | Google Scholar
  4. C. Lormeau, G. Falgarone, D. Roulot, and M. C. Boissier, “Rheumatologic manifestations of chronic hepatitis C infection,” Joint Bone Spine, vol. 73, no. 6, pp. 633–638, 2006. View at: Publisher Site | Google Scholar
  5. M. M. Ahmed, S. M. Berney, R. E. Wolf et al., “Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus,” American Journal of the Medical Sciences, vol. 331, no. 5, pp. 252–256, 2006. View at: Publisher Site | Google Scholar
  6. R. Canada, S. Chaudry, L. Gaber, B. Waters, A. Martinez, and B. Wall, “Polyarteritis nodosa and cryoglobulinemic glomerulonephritis related to chronic hepatitis C,” American Journal of the Medical Sciences, vol. 331, no. 6, pp. 329–333, 2006. View at: Publisher Site | Google Scholar
  7. A. M. Atta, P. Estevam, R. Paraná, C. M. Pereira, B. C. O. Leite, and M. L. B. Sousa-Atta, “Antiphospholipid antibodies in Brazilian hepatitis C virus carriers,” Brazilian Journal of Medical and Biological Research, vol. 41, no. 6, pp. 489–492, 2008. View at: Google Scholar
  8. A. di Muzio, B. Bonetti, M. Capasso et al., “Hepatitis C virus infection and myositis: a virus localization study,” Neuromuscular Disorders, vol. 13, no. 1, pp. 68–71, 2003. View at: Publisher Site | Google Scholar
  9. M. Ramos-Casals, J. Mañá, N. Nardi et al., “Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases,” Medicine (Baltimore), vol. 84, no. 2, pp. 69–80, 2005. View at: Publisher Site | Google Scholar
  10. A. Antonelli, C. Ferri, S. M. Ferrari, M. Colaci, D. Sansonno, and P. Fallahi, “Endocrine manifestations of hepatitis C virus infection,” Nature Clinical Practice Endocrinology and Metabolism, vol. 5, no. 1, pp. 26–34, 2009. View at: Publisher Site | Google Scholar
  11. P. Martin and F. Fabrizi, “Hepatitis C virus and kidney disease,” Journal of Hepatology, vol. 49, no. 4, pp. 613–624, 2008. View at: Publisher Site | Google Scholar
  12. P. Cacoub and D. Saadoun, “Hepatitis C virus infection induced vasculitis,” Clinical Reviews in Allergy and Immunology, vol. 35, no. 1-2, pp. 30–39, 2008. View at: Publisher Site | Google Scholar
  13. A. J. de Almeida, M. Campos-de-Magalhães, C. L. Antonietti et al., “Autoimmune thrombocytopenia related to chronic hepatitis C virus infection,” Hematology, vol. 14, no. 1, pp. 49–58, 2009. View at: Publisher Site | Google Scholar
  14. C. Ferri, A. Antonelli, M. T. Mascia et al., “B-cells and mixed cryoglobulinemia,” Autoimmunity Reviews, vol. 7, no. 2, pp. 114–120, 2007. View at: Publisher Site | Google Scholar
  15. M. Victor, R. D. Adams, and E. L. Mancall, “A restricted form of cerebellar cortical degeneration occurring in alcoholic patients,” Archives of Neurology, vol. 1, no. 6, pp. 579–688, 1959. View at: Google Scholar
  16. A. J. Bastian, J. W. Mink, B. A. Kaufman, and W. T. Thach, “Posterior vermal split syndrome,” Annals of Neurology, vol. 44, no. 4, pp. 601–610, 1998. View at: Publisher Site | Google Scholar
  17. G. Sechi, “Prognosis and therapy of Wernicke's encephalopathy after obesity surgery,” American Journal of Gastroenterology, vol. 103, no. 12, p. 3219, 2008. View at: Publisher Site | Google Scholar
  18. A. Von Drygalski and D. A. Andris, “Anemia after bariatric surgery: more than just iron deficiency,” Nutrition in Clinical Practice, vol. 24, no. 2, pp. 217–226, 2009. View at: Publisher Site | Google Scholar
  19. S. Jayaram, A. Soman, S. Tarvade, and V. Londhe, “Cerebellar Ataxia due to isolated Vitamin E deficiency,” Indian Journal of Medical Sciences, vol. 59, no. 1, pp. 20–23, 2005. View at: Google Scholar
  20. T. W. Clarkson, “The toxicology of mercury,” Critical Reviews in Clinical Laboratory Sciences, vol. 34, no. 4, pp. 369–403, 1997. View at: Google Scholar
  21. M. F. Gordon, R. I. Abrams, D. B. Rubin, W. B. Barr, and D. D. Correa, “Bismuth toxicity,” Neurology, vol. 44, no. 12, p. 2418, 1994. View at: Google Scholar
  22. M. Hadjivassiliou, D. S. Sanders, N. Woodroofe, C. Williamson, and R. A. Grünewald, “Gluten ataxia,” Cerebellum, vol. 7, no. 3, pp. 494–498, 2008. View at: Publisher Site | Google Scholar
  23. M. Sue, A. Yoshihara, T. Otani, Y. Tsuchida, M. Higa, and N. Hiroi, “Characteristics of fulminant type 1 diabetes mellitus,” Medical Science Monitor, vol. 14, no. 10, pp. 97–101, 2008. View at: Google Scholar
  24. M. C. Dalakas, “Advances in the pathogenesis and treatment of patients with stiff person syndrome,” Current Neurology and Neuroscience Reports, vol. 8, no. 1, pp. 48–55, 2008. View at: Publisher Site | Google Scholar
  25. S. Matà, G. C. Muscas, I. Naldi et al., “Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies,” Journal of Neuroimmunology, vol. 199, no. 1-2, pp. 155–159, 2008. View at: Publisher Site | Google Scholar
  26. I. Markakis, E. Alexiou, M. Xifaras, G. Gekas, and A. Rombos, “Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase,” Clinical Neurology and Neurosurgery, vol. 110, no. 6, pp. 619–621, 2008. View at: Publisher Site | Google Scholar
  27. S. Vulliemoz, G. Vanini, A. Truffert, C. Chizzolini, and M. Seeck, “Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 2, pp. 187–189, 2007. View at: Publisher Site | Google Scholar
  28. A. Saiz, Y. Blanco, L. Sabater et al., “Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association,” Brain, vol. 131, no. 10, pp. 2553–2563, 2008. View at: Publisher Site | Google Scholar
  29. B. B. Murinson and J. B. Guarnaccia, “Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease,” Neurology, vol. 71, no. 24, pp. 1955–1958, 2008. View at: Publisher Site | Google Scholar
  30. D. P. Bogdanos and E. I. Rigopoulou, “Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes,” Diabetes Research and Clinical Practice, vol. 77, no. 1, pp. 155–156, 2007. View at: Publisher Site | Google Scholar
  31. W. F. Hickey, “Basic principles of immunological surveillance of the normal central nervous system,” GLIA, vol. 36, no. 2, pp. 118–124, 2001. View at: Publisher Site | Google Scholar
  32. C. F. Evans, M. S. Horwitz, M. V. Hobbs, and M. B. A. Oldstone, “Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease,” Journal of Experimental Medicine, vol. 184, no. 6, pp. 2371–2384, 1996. View at: Publisher Site | Google Scholar
  33. G. Lauria, D. Pareyson, M. G. Pitzolu, and E. Bazzigaluppi, “Excellent response to steroid treatment in anti-GAD cerebellar ataxia,” Lancet Neurology, vol. 2, no. 10, pp. 634–635, 2003. View at: Publisher Site | Google Scholar
  34. M. C. Dalakas, “The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies,” Journal of Neurology, vol. 252, supplement 1, pp. I19–I25, 2005. View at: Google Scholar
  35. L. M. Levy, M. C. Dalakas, and M. K. Floeter, “The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of γ-aminobutyric acid,” Annals of Internal Medicine, vol. 131, no. 7, pp. 522–530, 1999. View at: Google Scholar
  36. S. de Vita, L. Quartuccio, and M. Fabris, “Rituximab in mixed cryoglobulinemia: increased experience and perspectives,” Digestive and Liver Disease, vol. 39, supplement 1, pp. S122–S128, 2007. View at: Publisher Site | Google Scholar
  37. G. Cervetti, S. Mechelli, R. Riccioni, S. Galimberti, F. Caracciolo, and M. Petrini, “High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders asociated with systemic autoimmune diseases,” Clinical and Experimental Rheumatology, vol. 23, no. 6, pp. 877–880, 2005. View at: Google Scholar
  38. J. N. Acharya and V. H. Pacheco, “Neurologic complications of hepatitis C,” Neurologist, vol. 14, no. 3, pp. 151–156, 2008. View at: Publisher Site | Google Scholar
  39. L. E. Wilson, D. Widman, S. H. Dikman, and P. D. Gorevic, “Autoimmune disease complicating antiviral therapy for hepatitis C virus infection,” Seminars in Arthritis and Rheumatism, vol. 32, no. 3, pp. 163–173, 2002. View at: Publisher Site | Google Scholar

Copyright © 2011 Amer Awad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.